EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer

Biochemical Pharmacology

Volumn 70, Issue 11, 2005, Pages 1568-1578

  Huether, Alexander ^a   Höpfner, Michael ^a   Baradari, Viola ^a   Schuppan, Detlef ^b   Scherübl, Hans ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chemoprevention; Cisplatin; Doxorubicin; EGF; Epidermal growth factor receptor; Erbitux ; IGF; Insulin like growth factor receptor; Statins; Tarceva

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; ANTINEOPLASTIC AGENT; CASPASE 3; CETUXIMAB; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUINDOSTATIN; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MUTANT PROTEIN; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TIME; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; FATTY ACIDS, MONOUNSATURATED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIVER NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TYRPHOSTINS;

EID: 27544497021     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.09.007     Document Type: Article

References (45)

1. H. El Serag, J.A. Davila, N.J. Petersen, and K.A. McGlynn The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update Ann Intern Med 139 2003 817 823
2. K.A. McGlynn, L. Tsao, A.W. Hsing, S.S. Devesa, and J.F. Fraumeni International trends and patterns of primary liver cancer Int J Cancer 94 2001 290 296
3. H.B. El Serag, A.C. Mason, and C. Key Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States Hepatology 33 2001 62 65
4. J.M. Llovet, A. Burroughs, and J. Bruix Hepatocellular carcinoma Lancet 362 2003 1907 1917
5. M. Daveau, M. Scotte, A. Francois, C. Coulouarn, G. Ros, and Y. Tallet Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma Mol Carcinog 36 2003 130 141
6. Y.N. Zhao, J. Cao, F.X. Wu, C. Ou, W.P. Yuan, and Q.G. Mo Expression and significance of EGF mRNA and EGFR mRNA in hepatocellular carcinoma Ai Zheng 23 2004 762 766
7. Y. Ito, T. Takeda, M. Sakon, M. Tsujimoto, S. Higashiyama, and K. Noda Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma Br J Cancer 84 2001 1377 1383
8. S. Kira, T. Nakanishi, S. Suemori, M. Kitamoto, Y. Watanabe, and G. Kajiyama Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma Liver 17 1997 177 182
9. L.A. DeCicco, J. Kong, and D.P. Ringer Carcinogen-induced alteration in liver epidermal growth factor receptor distribution during the promotion stage of hepatocarcinogenesis in rat Cancer Lett 111 1997 149 156
10. J. Baselga Why the epidermal growth factor receptor? The rationale for cancer therapy Oncologist 7 2002 2 8
11. C.L. Arteaga Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7 2002 31 39
12. Z. Fan, Y. Lu, X.P. Wu, and J. Mendelsohn Antibody-induced epidermal growth-factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma-cells J Biol Chem 269 1994 27595 27602
13. M. Prewett, P. Rockwell, R.F. Rockwell, N.A. Giorgio, J. Mendelsohn, and H.I. Scher The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma J Immunother 19 1996 419 427
14. P. Carter Improving the efficacy of antibody-based cancer therapies Nat Rev Cancer 1 2001 118 129
15. P.M. Harari Epidermal growth factor receptor inhibition strategies in oncology Endocr Relat Cancer 11 2004 689 708
16. D.P. Aden, A. Fogel, S. Plotkin, I. Damjanov, and B.B. Knowles Controlled synthesis of Hbsag in a differentiated human-liver carcinoma-derived cell-line Nature 282 1979 615 616
17. H. Nakabayashi, K. Taketa, K. Miyano, T. Yamane, and J. Sato Growth of human hepatoma-cell lines with differentiated functions in chemically defined medium Cancer Res 42 1982 3858 3863
18. R.J. Gillies, N. Didier, and M. Denton Determination of cell number in monolayer-cultures Anal Biochem 159 1986 109 113
19. D.W. Nicholson, A. Ali, N.A. Thornberry, J.P. Vaillancourt, C.K. Ding, and M. Gallant Identification and inhibition of the Ice/Ced-3 protease necessary for mammalian apoptosis Nature 376 1995 37 43
20. L. Vindelov, and I.J. Christensen An integrated set of methods for routine flow cytometric DNA analysis Methods Cell Biol 33 1990 127 137
21. M. Hopfner, A.P. Sutter, A. Huether, G. Ahnert-Hilger, and H. Scherubl A novel approach in the treatment of neuroendocrine gastrointestinal tumors: Additive antiproliferative effects of interferon-gamma and meta- iodobenzylguanidine BMC Cancer 4 2004 23
22. A. Huether, M. Hopfner, A.P. Sutter, D. Schuppan, and H. Scherubl Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics J Hepatol 43 2005 661 669
23. B.W. Wu, Y. Wu, J.L. Wang, J.S. Lin, S.Y. Yuan, and A. Li Study on the mechanism of epidermal growth factor-induced proliferation of hepatoma cells World J Gastroenterol 9 2003 271 275
24. M. Hopfner, A.P. Sutter, A. Huether, D. Schuppan, M. Zeitz, and H. Scherubl Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma J Hepatol 41 2004 1008 1016
25. N. Magne, J.L. Fischel, A. Dubreuil, P. Formento, M.F. Poupon, and P. Laurent-Puig Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antproliferative effect of ZD 1839 ('Iressa') Br J Cancer 86 2002 1518 1523
26. P.C. Bishop, T. Myers, R. Robey, D.W. Fry, E.T. Liu, and M.V. Blagosklonny Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family Oncogene 21 2002 119 127
27. T.K. Lee, T.C. Lau, and I.O. Ng Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines Cancer Chemother Pharmacol 49 2002 78 86
28. S.W. Lowe, H.E. Ruley, T. Jacks, and D.E. Housman P53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 74 1993 957 967
29. A.J. Levine p53, the cellular gatekeeper for growth and division Cell 88 1997 323 331
30. M.B. Kastan, O. Onyekwere, D. Sidransky, B. Vogelstein, and R.W. Craig Participation of P53 protein in the cellular-response to DNA damage Cancer Res 51 1991 6304 6311
31. W.S. Eldeiry, J.W. Harper, P.M. Oconnor, V.E. Velculescu, C.E. Canman, and J. Jackman Waf1/Cip1 Is Induced in P53-mediated G(1) arrest and apoptosis Cancer Res 54 1994 1169 1174
32. Q.M. Zhan, K.A. Lord, I. Alamo, M.C. Hollander, F. Carrier, and D. Ron The Gadd and Myd genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell-growth Mol Cell Biol 14 1994 2361 2371
33. N. Sugawa, A.J. Ekstrand, C.D. James, and V.P. Collins Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas Proc Natl Acad Sci USA 87 1990 8602 8606
34. J.G. Scharf, and T. Braulke The role of the IGF axis in hepatocarcinogenesis Horm Metab Res 35 2003 685 693
35. Hopfner M, Huether A, Sutter AP, Maaser K, Schuppan D, Scherubl H. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in hepatocellular cancer, 2005, unpublished work.
36. A. Chakravarti, J.S. Loeffler, and N.J. Dyson Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling Cancer Res 62 2002 200 207
37. P.A. Philip, M.R. Mahoney, C. Allmer, J. Thomas, H.C. Pitot, G. Kim, R.C. Donehower, T. Fitch, J. Picus, and C. Erlichman Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer J Clin Oncol 23 2005 6657 6663
38. S.M. Huang, E.A. Armstrong, S. Benavente, P. Chinnaiyan, and P.M. Harari Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor Cancer Res 64 2004 5355 5362
39. M.A. Fabian, W.H. Biggs, D.K. Treiber, C.E. Atteridge, M.D. Azimioara, and M.G. Benedetti A small molecule-kinase interaction map for clinical kinase inhibitors Nat Biotechnol 23 2005 329 336
40. A. Gebhardt, and A. Niendorf Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines J Cancer Res Clin Oncol 121 1995 343 349
41. G. Paragh, P. Kertai, P. Kovacs, G. Paragh Jr., P. Fulop, and G. Foris HMG CoA reductase inhibitor fluvastatin arrests the development of implanted hepatocarcinoma in rats Anticancer Res 23 2003 3949 3954
42. Sutter AP, Maaser K, Hopfner M, Huether A, Schuppan D, Scherubl H. Growth inhibition and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliverative action with peripheral benzodiazepine receptor ligands. J Hepatol, in press.
43. Khurana V, Saluja A, Caldito G, Fort C, Schiff ER. Statins are protective against hepatocellular cancer in patients with hepatitis C virus infection: Half a million US veterans' study. Abstract S1535, DDW 2005, Chicago, IL. May 14-18, 2005.
44. J. Bruix, M. Sala, and J.M. Llovet Chemoembolization for hepatocellular carcinoma Gastroenterology 127 2004 S179 S188
45. J. Mendelsohn, and Z. Fan Epidermal growth factor receptor family and chemosensitization J Natl Cancer Inst 89 1997 341 343